-
ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries
PharmaSources.com
April 12, 2022
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
-
Could COVID-19 vaccines be swallowed?
EuropeanPharmaceuticalReview
February 10, 2022
New pre-clinical research demonstrates the potential of gastric autoinjectors to deliver mRNA in sufficient quantities for vaccination.
-
Coriolis Pharma Opens New ATMP Formulation Development Facilities
B3Cnewswire
February 07, 2022
Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of biopharmaceuticals and vaccines...
-
DCGI approves “Conditional Market Authorisation” of Covaxin and Covishield
ExpressPharma
January 28, 2022
The approval pathways through this route are fast-tracked with certain conditions to enhance the access to certain pharmaceuticals for meeting the emerging needs of drugs or vaccines
-
Air of optimism surrounds lung cancer vaccine
pharmatimes
January 18, 2022
Cancer Research UK announces clinical trial for most common type of lung cancer
-
While Omicron continues to dominate across the world, COVID-19 travel requirements remain
pharmatimes
January 15, 2022
The scandal surrounding Novak Djokovic’s entry into Australia, following his vaccine exemption, has sparked outcry on both a national and global scale.
-
New study adds more evidence for Omicron immune evasion
WorldPharmaNews
December 27, 2021
A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, S.A.R., China, adds more evidence that the omicron variant can evade the immune protection conferred by vaccines...
-
Vaccines still provide ‘significant protection’ against severe COVID-19
PharmaTimes
December 16, 2021
Omicron has been the latest variant to test the effectiveness of COVID-19 vaccines.
-
British Study Shows Vaccines Weaken Against Omicron, but Boosters Help
Drugs
December 14, 2021
The ability of two-dose COVID-19 vaccines to protect against symptomatic infection by the omicron variant falls significantly short, but a booster shot provides considerable protection...
-
Effectiveness of mRNA COVID-19 Vaccines Lower at ≥120 Days
Drugs
December 10, 2021
The vaccine effectiveness (VE) of both the Moderna and Pfizer-BioNTech mRNA vaccines declined at ≥120 days after the second dose, with higher VE and antibody levels for Moderna than Pfizer-BioNTech recipients...